The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Astrana Health’s second quarter was met with a positive market response, as management highlighted several drivers behind the results. The company saw continued demand from payer and provider partners, maturation of value-based care cohorts, and disciplined medical cost trend management. CEO Brandon Sim attributed operating leverage improvements to the company’s proprietary AI-native healthcare operating system, which has enabled more efficient workflows and reduced general and administrative ex

Revenue jumped 49% to $972.5 million as adjusted EPS hit record $0.80.

Healthcare services company Astrana Health missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 48.5% year on year to $972.5 million. Next quarter’s revenue guidance of $1.02 billion underwhelmed, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.80 per share was 9.6% above analysts’ consensus estimates.

Astrana Health now sits on a modestly higher fair value estimate, with the modeled price moving from about US$47.11 to about US$50.13 per share. That shift lines up with analyst commentary that weighs execution on Prospect integration, value based care positioning, and full risk membership growth against a current price target band that runs from the mid US$40s to the mid US$60s. As you read on, you will see how this evolving narrative might shape how you track Astrana Health from here. Stay...

Astrana Health Inc (ASTH) delivers 49% revenue growth and raises full-year adjusted EBITDA guidance to $255-$280 million.

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +29.03% and -0.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Astrana Health (NASDAQ:ASTH) reported second-quarter 2026 revenue of $973 million, up 49% from a year earlier, while adjusted EBITDA increased 43% to $69 million. Adjusted diluted earnings per share reached a record $0.80, up 45% year over year, as the company cited growth in value-based care arrang

Healthcare services company Astrana Health fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 48.5% year on year to $972.5 million. Next quarter’s revenue guidance of $1.02 billion underwhelmed, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.80 per share was 9.6% above analysts’ consensus estimates.

Astrana Health stock has surged 86.5% year to date, yet the company still carries a low overall value score and screens as expensive on traditional valuation multiples, which raises the question of how much of the recent optimism is already reflected in the price. The 86.5% year to date gain points to strong momentum, but also means new buyers are paying a much higher entry price than they could earlier in the year. Recent shared savings performance and revenue growth can support high...

The past six months have been a windfall for Astrana Health’s shareholders. The company’s stock price has jumped 79%, hitting $49.01 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.